PCSK9抑制剂在冠状动脉粥样硬化性心脏病治疗中的应用

Application of PCSK9 Inhibitor in the Treatment of Coronary Atherosclerotic Heart Disease

低密度脂蛋白胆固醇(LDL-C)血浆水平升高是动脉粥样硬化性心血管疾病(ASCVD)的主要危险因素。他汀类药物虽然能够有效降低LDL-C水平,但仍有部分患者无法达到降脂目标或者无法耐受。目前大量研究表明前蛋白转化酶枯草溶菌素9(PCSK9)与血浆LDL-C紧密相关,抑制PCSK9可以有效降低LDL-C水平及ASCVD发生率。本文主要对PCSK9机制以及PCSK9抑制剂治疗冠状动脉粥样硬化性心脏病的新研究进展作一综述。

Elevated plasma levels of low-density lipoprotein cholesterol(LDL-C)are a major risk factor for atherosclerotic cardiovascular disease(ASCVD).Although statins can effectively reduce LDL-C levels,some patients are still unable to achieve lipid-lowering goals or are intolerable.A large number of studies have shown that the proprotein convertase subtilisin 9(PCSK9)is closely related to plasma LDL-C,and inhibition of PCSK9 can effectively reduce the level of LDL-C and ASCVD.This article reviews the recent advances in PCSK9 mechanisms and PCSK9 inhibitors in the treatment of coronary atherosclerotic heart disease.